US › Healthcare

PolyPid (PYPD)

US · Healthcare · Biotechnology

$5.03-3.45%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-7.8M

EPS

$-0.35

EPS estimate

$-0.34

EPS came in at -0.35 against a street estimate of -0.34 — a miss of 2.9%.

Key statistics

Market cap

$104.6M

Forward P/E

0.0

P/B

19.45

Book value

$0.27

EPS (TTM)

$-1.31

52-week high

$5.73

52-week low

$3.06

50-day MA

$4.87

200-day MA

$4.54

Beta

1.42

Analyst view

Analysts rate PolyPid a buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $11.75.

Shareholding

Insiders

17.79%

Institutions

34.55%

Largest institutional holders

Fund	Stake
AIGH Capital Management, LLC	7.41%
Rosalind Advisors, Inc.	2.94%
Dafna Capital Management LLC	1.02%
Morgan Stanley - Brokerage Accounts	0.87%
J. Goldman & Co LP	0.74%
ADAR1 Capital Management LLC	0.51%
Symmetry Peak Management LLC	0.50%
Quadrature Capital Limited	0.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PolyPid — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.